NCT02149667

Post Market Clinical Follow-up Study Protocol for DYNASTY® BioFoam® Acetabular Components

• Status: Active Not Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 48 (actual)
• Sponsor: MicroPort Orthopedics Inc. · Industry
• Sex: All
• Age: 21 Years
• Healthy volunteers: Not accepted

Summary

Sponsor is conducting this post market clinical follow-up (PMCF) study to evaluate the safety and efficacy of its total hip arthroplasty (THA) components marketed in the European Union (EU) . These types of studies are required by regulatory authorities for all THA devices that do not have medium to long-term clinical evidence available at the time of gaining approval to market in the EU. This study has been designed in accordance with MEDDEV 2.12/2 rev 2.

Detailed description

Total hip arthroplasty (THA) has been performed since the early 1920s and is generally considered to be one of the most successful orthopedic surgeries performed. The 8th Annual Report from the National Joint Registry of England and Wales reported 95.3% component survivorship at 7 years for over 300,000 THA implantations. MicroPort Orthopedics, Inc. (MPO) currently markets several THA components throughout the world, including the European Union (EU). As part of the process for gaining approval to market in the EU, MPO is conducting this post market clinical follow-up (PMCF) study to evaluate the safety and efficacy of these THA components. The objectives of this study are to evaluate component survivorship and total functional outcome scores of implanted subjects at out to 10 years follow-up.

Conditions

• Joint Disease

Interventions

Type	Name	Description
DEVICE	total hip arthroplasty implant

Timeline

• Start date: 2014-12-01
• Primary completion: 2027-12-01
• Completion: 2028-12-01
• First posted: 2014-05-29
• Last updated: 2023-06-07

Locations

1 site across 1 country: Canada